A drug launch turns regulatory approval into a test of clinical demand, patient access and commercial execution. Physicians must see a reason to prescribe. Patients must reach treatment, afford their share of the cost and accept the practical burden. The manufacturer must supply the product and support the process without spending more than the opportunity can justify. For investors, the task is to identify where that process works, where patients drop out and whether the economics improve as use grows. Within biotech commercialisation and market economics, launch analysis connects a drug’s scientific promise with the evidence needed to support a revenue forecast.
A drug launch is a conversion process
Start with the path from a potentially suitable patient to a paid treatment. Each step has its own denominator, delay and reason for failure. A physician can prescribe enthusiastically while patients struggle to secure coverage. An insurer can cover a medicine while treatment centers lack appointment capacity. Strong demand at one stage does not establish success at the next. The starting population also needs discipline: disease prevalence is not a launch forecast. Build the initial pool through an assessment of eligible and reachable patients, then examine how many can move through the actual treatment pathway.
| Stage | What must happen | Useful evidence |
|---|---|---|
| Identification | A suitable patient receives the necessary diagnosis or testing. | Completed tests, eligible referrals and referral sources. |
| Clinical decision | The physician recommends treatment and the patient accepts. | Treatment decisions, prescriptions and reasons for declining. |
| Access | Coverage, documentation and affordability issues are resolved. | Approval rates, appeals and time to authorization. |
| Treatment start | The patient receives the first paid treatment. | Paid fills, administrations or completed procedures. |
| Continued use | The patient continues for the appropriate treatment duration. | Refills, repeat administrations and discontinuations. |
| Revenue conversion | Treatment generates recognized net product revenue. | Net sales, deductions and the accounting recognition policy. |
Approval establishes a different milestone from adoption. Leqembi, for example, received traditional FDA approval on July 6, 2023, after its confirmatory trial verified clinical benefit. The approval announcement also described treatment initiation in patients with mild cognitive impairment or mild dementia stage of Alzheimer’s disease, with confirmed amyloid pathology in the trial population. Those boundaries matter when defining the launch opportunity; an Alzheimer’s diagnosis alone was not a sufficient commercial denominator. The FDA’s Leqembi approval announcement provides the evidence and patient context behind that milestone.
What changes a physician’s prescribing decision?
Benefit must justify a change in practice
A launch thesis should identify the decision the physician is being asked to change. Is the new medicine replacing a familiar treatment, adding another step or offering an option where none existed? The answer determines the evidence needed. A physician treating a stable patient may require a persuasive reason to switch, even when a new drug produced positive trial results. For an untreated patient with serious disease, the decision may look different. Examine the size and relevance of the benefit, the comparison treatment and the patients studied. A disciplined process for reading clinical trial results helps separate evidence that supports prescribing from evidence that mainly supports a promotional headline.
Translate differentiation into a practical choice. A longer dosing interval might reduce visits, but does it require a more burdensome administration? Better efficacy might support use in higher risk patients, while tolerability concerns discourage use elsewhere. Avoid assuming every eligible physician will interpret the tradeoff alike. Segment adoption by patient type, treatment setting and the existing standard of care. The commercial question is whether the advantage changes behavior within a reachable group. That assessment belongs alongside competition from established treatments and competing pipelines, rather than a comparison with an empty market in which the new product faces no resistance.
Workflow can change the adoption curve
Clinical requirements can add work long after the initial approval. On August 28, 2025, the FDA announced an additional, earlier monitoring MRI before the third Leqembi infusion to help identify amyloid related imaging abnormalities with edema, or ARIA-E. The agency also stated that it was requiring the prescribing information to include that earlier scan. This dated example shows why a launch model cannot freeze the treatment pathway at approval. Safety monitoring can change the number and timing of appointments needed to treat patients. The FDA communication on earlier Leqembi MRI monitoring documents the change; its effect on a forecast requires a separate operational assessment.
Model the practical consequence rather than assuming that extra work automatically destroys demand. Ask whether imaging appointments are available, who reviews the results and whether treatment can proceed on schedule. A well staffed specialist center may absorb a requirement that strains a smaller practice. The relevant measure is completed treatment capacity. A count of interested physicians tells investors little about that capacity unless the company also shows that practices can identify patients, complete the required work and move them into treatment.
Patient access: coverage must turn into treatment
Coverage announcements describe potential access, not completed access. Read the conditions attached to coverage and ask how a patient satisfies them. Prior authorization, documentation of previous treatment or a required diagnostic test can create separate points of delay. Affordability adds another question: what does the patient actually pay after insurance and any applicable assistance? Keep the reimbursement analysis focused on its effect on conversion, timing and net revenue. The broader mechanics of drug pricing, reimbursement and market access deserve their own assessment. For launch monitoring, the useful distinction is between patients who appear covered on paper and those who receive a paid treatment.
Leqembi’s initial traditional approval provides a concrete example. The Medicare coverage framework announced on July 6, 2023, required an eligible diagnosis, documented evidence of beta-amyloid plaque and a physician participating in a qualifying registry with an appropriate clinical team and follow-up care. Broader coverage therefore still involved a defined care and evidence collection pathway. The CMS announcement of Medicare coverage following traditional approval set out those conditions. For investors studying that launch period, counting covered beneficiaries without considering the pathway would have overstated what the coverage announcement established.
Patient support should be judged by resolved barriers. More enrollment forms might indicate rising demand, or a growing queue of unresolved cases. Request the median time from referral to treatment, the share of cases still pending and the reasons patients abandon the process. Where available, compare patients referred in the same month and follow their progress over time. This avoids a common reporting trap: recent referrals inflate the queue before they have had a reasonable opportunity to start, making an improving launch look worse than it is.
Sales execution: measure productive use, not activity
Match the commercial organization to the prescribing decision. A medicine used by a concentrated group of specialists calls for a different operating plan from a product intended for broad primary care use. Evaluate account selection, access support and the route from physician interest to an actual order. Sales calls, conference attendance and educational events measure activity. They do not establish productive prescribing. A more useful question is whether an account begins treating suitable patients and then continues to do so. Separate newly contacted accounts from established ones; otherwise expansion into new territories can obscure weak performance in accounts that have already received sustained support.
Hospital launches need an account level view. Consider a hypothetical product that has gained a formulary listing but is absent from the electronic ordering process used by the relevant department. The institution has approved the medicine, yet routine use may still require extra steps. Investors should ask what “account activated” means: a contract signed, staff trained, an order placed or the first patient treated? These are different achievements. Compare accounts using the same definition, then examine whether treatment volumes grow after activation. A rising number of nominally active accounts can coexist with little change in patient starts.
Supply belongs in the same review. Before crediting a sales organization with an adoption shortfall, check whether the product was available in the required presentation and at the intended treatment site. Conversely, manufacturing additional inventory does not prove that patients want it. Keep production readiness separate from demand, while connecting both to completed treatments. For products with complicated supply chains, the questions in biotech manufacturing, capacity and quality control become part of launch execution. The commercial team cannot turn an unavailable dose into revenue through a better presentation.
Read launch metrics with consistent definitions
Build a launch scorecard before the first earnings update, then preserve its definitions. Record whether each measure is quarterly or cumulative, domestic or global, paid or free. Check whether prescription data count people, prescriptions or standardized units. A larger prescription count can reflect longer treatment, more frequent dispensing or more patients; the implications differ. Use financial filings and other primary research sources to reconcile management’s operating measures with reported sales. When a company changes a definition, retain both versions where possible. A better looking number is not necessarily evidence of better execution.
| Metric | What it helps assess | What to check |
|---|---|---|
| New paid starts | Conversion into revenue generating treatment. | Whether free treatment and restarts are excluded. |
| Active prescribers | Breadth of clinical adoption. | The time window and minimum activity required. |
| Repeat prescribing | Use beyond a physician’s initial trial of the product. | Whether physicians have had time to treat another suitable patient. |
| Time to treatment | Friction between a decision and treatment delivery. | Pending cases, abandonment and the distribution around the median. |
| Persistence | Continued use of an ongoing therapy. | Follow-up duration, treatment interruptions and reasons for stopping. |
| Net product revenue | Recognized commercial sales. | Inventory effects, deductions, geographic mix and recognition timing. |
Accounting policy can place revenue at different points in the pathway. Vertex’s 2025 Form 10-K states that revenue recognition typically occurs on delivery for its small molecule products, including JOURNAVX, and on infusion for its gene therapy products, including CASGEVY. The filing also describes estimates for rebates, discounts and other adjustments used to calculate net product revenue. These policies explain why shipment, treatment and revenue measures should not be treated as interchangeable. The Vertex 2025 Form 10-K revenue recognition disclosures provide the company’s accounting basis, rather than an assumption that every product generates reported sales at the same operational milestone.
Use separate bridges for revenue growth and patient growth. In the revenue bridge, isolate volume, realized net price, geographic mix and any disclosed inventory movement. In the patient bridge, distinguish new starts from continuing patients and those stopping treatment. Cash collection is another measure again. Do not interpret a quarter’s revenue as cash immediately available to fund operations. Where management does not disclose enough detail to reconcile the measures, preserve the uncertainty in the model instead of producing an apparently exact patient count by dividing sales by the list price.
Why cell therapy launches need a different scorecard
CASGEVY illustrates the distance between intermediate treatment milestones and completed infusions. For the full year 2025, Vertex reported 147 people globally undergoing their first cell collection and 64 receiving infusions, including 30 in the fourth quarter. It reported approximately $116 million of CASGEVY revenue for that year. These are historical figures, published in the company’s February 12, 2026 results release, rather than a current launch forecast. The Vertex full year 2025 launch results show why a treatment pathway needs more than a single enrollment or sales measure.
Do not divide 64 by 147 and label the answer a conversion rate. The patients collected during a calendar year are not necessarily the same patients infused during that year. Some collections can lead to treatment later; some infusions can follow collections from an earlier period. A valid conversion analysis follows the same group from one milestone to the next, with sufficient follow-up. Without that information, the figures establish activity at different stages, not the probability that an individual patient completes treatment. They also do not, by themselves, establish whether the gap reflects scheduling, clinical decisions or another cause.
For a one time treatment, repeat prescribing means treating another patient, rather than refilling the same patient’s prescription. The scorecard should therefore emphasize referrals, completed preparation, treatment capacity and delivery. A count of authorized centers needs a companion measure of productive centers and patients treated per center. The scientific and operational issues covered in cell therapy manufacturing and commercial constraints help frame the questions. The investment analysis should then test whether the disclosed operating milestones support the proposed revenue timing.
Build a launch forecast from patient cohorts
A useful launch model starts with patients entering the pathway during each period and follows them through treatment. This makes delays visible and prevents the same patient appearing as a new opportunity in every quarter. For an ongoing therapy, calculate revenue from paid treatment months or another appropriate unit. For a one time therapy, use completed revenue generating treatments. Keep the launch operating model separate from the broader risk adjusted valuation of the pipeline. The operating model tests how commercial activity develops; the valuation then considers what those cash flows may be worth.
Consider a hypothetical cohort of 1,000 identified patients. Assume 40% meet the clinical criteria, half of that group reach a prescribing decision and accept treatment, 70% secure access, and 80% of those patients start within the forecast period. The result is 112 starts. These percentages are illustrative assumptions, not industry benchmarks. If each starter generates an average of two paid treatment months during the period at $1,000 net revenue per month, the cohort contributes $224,000. Multiplying 112 by a full year of treatment would produce a very different number, without support from the stated timing assumptions.
Stress the points where the evidence is weakest. If access improves but time to treatment lengthens, revenue can remain below expectations despite better eventual conversion. If patient starts rise while persistence falls, the launch may require more acquisition spending to support the same active population. Test these assumptions separately through sensitivity analysis of sales, timing and costs. Avoid fixing a weak forecast by increasing an unexplained market share percentage. Change the operating assumption responsible for the shortfall, and state what evidence would justify that change.
Separate a slow launch from a weak commercial proposition
A revenue miss identifies a forecasting error; it does not identify its cause. Diagnose the stage that failed before deciding whether the problem is temporary. A backlog caused by an access process might clear as cases progress. Low patient acceptance after a completed clinical discussion raises a different question. So does poor repeat prescribing after physicians gain experience. Compare performance against the company’s original launch assumptions, not a revised narrative that arrives after the miss. Give more weight to explanations supported by measurable changes in the pathway than to promises that awareness will improve next quarter.
- Evidence problem: Physicians see insufficient benefit to justify changing treatment.
- Access problem: Patients accept treatment but coverage or affordability prevents starts.
- Execution problem: Administrative, distribution or scheduling failures interrupt delivery.
- Capacity problem: Demand exceeds the treatment pathway’s available throughput.
Each diagnosis implies a different cost and timetable. Hiring more representatives is a questionable response to scarce treatment appointments. Discounting may improve access while weakening net revenue per patient. Adding centers can increase capacity, but the forecast still needs evidence that those centers will treat patients. Connect the proposed remedy to spending and the company’s cash burn and funding runway. A launch can retain a credible long term opportunity while requiring more capital than shareholders originally expected. Commercial progress and attractive financing terms are separate questions.
Before the next reporting period, write down the evidence that would confirm or reject the diagnosis. That might be a shorter referral queue, more paid starts from older referrals or higher treatment volume at established accounts. Specify the relevant period and denominator. If management stops reporting a measure that previously supported the launch thesis, seek a reconciliation rather than treating its disappearance as neutral. The next investment decision should rest on whether the operating evidence changed, and whether the share price already assumes a better outcome than that evidence supports.